- Combining AstraZeneca plc’s (NASDAQ: (AZN)) COVID-19 vaccine with a second dose from either Pfizer Inc (NYSE: PFE) – BioNTech SE ((NASDAQ: (BNTX))) or Moderna Inc’s (NASDAQ: MRNA) shot provides “good protection,” Denmark’s State Serum Institute (SSI) said.
- More than 144,000 Danish citizens, mostly healthcare frontline personnel and the elderly, received their first jab from AstraZeneca and subsequent shot from either Pfizer–BioNTech or Moderna, reports Reuters.
- “The study shows that fourteen days after a combined vaccination program, the risk of infection with SARS-CoV-2 is reduced by 88% compared to unvaccinated individuals,” the SSI said.
- That is a “high efficacy,” SSI added, comparable to the 90% efficacy rate of two doses from Pfizer–BioNTech‘s vaccine, confirmed in a different Danish study. But the study could not conclude whether the same protection applied to the Delta-variant.
- It also provided no efficacy data on COVID-19 related deaths or hospitalizations since none took place following the combined vaccination program.
- price Action: (AZN) shares are up 0.31% at $57.42 on the last check Monday.
- Photo by Johaehn from Pixabay
© 2021 Fintech Zoom.com. Fintech Zoom does not provide investment advice. All rights reserved.
((BNTX)), Pfizer, Inc. (NYSE:PFE) – Combining AstraZeneca, mRNA COVID-19 Vaccines Show Efficacy In Danish Study: Reuters
Tags: Moderna Stock, NASDAQ: MRNA, MRNA Stock
Stock Market, Latest News on C N N.